17.06.2010 • News

Descartes Acquires Routing International

Descartes Systems Group, a federated global logistics network, acquired privately-held Belgian-based Routing International, a developer and distributor of optimized route planning solutions. Routing International's solutions join Descartes' MRM 2.0 solution suite, which combine optimized real-time planning with wireless mobile technology to manage resources in motion.

"The addition of Routing International's solutions and customers expands Descartes' MRM 2.0 size, reach and scope in Europe," said Daniel Verougstraete, vice president, MRM EMEA at Descartes and former CEO of Routing International. "Combined, we have an end-to-end product footprint and local operations to service small to large enterprises in Europe."

Since 1990, Routing International has specialized in optimized route planning for distribution-intensive organizations. The company's flagship solution suite, WinRoute, and dedicated consultants help enterprises of all sizes and across industries to optimize distribution planning to improve the productivity and performance of their operations.

Routing International's solutions enhance Descartes' MRM 2.0 suite of solutions in the areas of advanced routing algorithms, advanced geocoding, historical traffic support and complex moveable and multi-compartment routing for food service and fuel industries. Routing International's pan-European customer base adds more than 200 members to Descartes' federated Global Logistics Network (GLN).

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.